BioNTech and OncoC4’s Gotistobart Nearly Doubles Survival in Previously Treated Squamous NSCLC
Updated PRESERVE-003 data showed median overall survival of 18.5 months with the CTLA-4 antibody, compared with 10 months for docetaxel. The result is encouraging, but confirmation must come from the ongoing pivotal stage of the Phase 3 trial. BioNTech…
Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million
The Swiss pharmaceutical group has exercised its option to acquire Sironax’s technology for transporting large therapeutic molecules across the blood-brain barrier. Novartis has exercised its exclusive option to acquire full global rights to Sironax’s…
GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
GSK is expanding its relationship with China’s Chimagen Biosciences, agreeing to acquire global rights to an experimental trispecific T-cell engager for multiple myeloma in a transaction worth up to $750 million. The agreement, announced September 15,…
RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC
The PD-1/VEGF bispecific antibody produced high response rates with chemotherapy across squamous and non-squamous lung cancer cohorts, supporting its advancement into Phase 3 development. RemeGen and AbbVie have reported strong early clinical results for…
Roche and MediLink’s Tam-Peli Reduces Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial
Roche and MediLink Therapeutics have reported a substantial survival benefit for tambotatug pelitecan, the experimental B7-H3-targeted antibody-drug conjugate known as Tam-Peli, in patients with relapsed small-cell lung cancer. In the Chinese Phase 3…
Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…
GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…
Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
Hangzhou-based Unike Biopharma has completed an angel financing round worth tens of millions of RMB, giving the young biotech fresh capital to advance a broad pipeline of long-acting protein and peptide therapeutics built around its proprietary ZT…
1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
1cBio has struck a regional licensing deal with Hong Kong-based Lee’s Pharmaceutical Holdings to advance OC-3, its next-generation selective PARP1 inhibitor, across Greater China and parts of Southeast Asia. Under the agreement announced September 9,…